
Biocon Limited has informed the Exchange regarding a press release dated December 22, 2023, titled "Biocon Biologics Partners with Sandoz for the Distribution of Adalimumab BS Subcutaneous Injection [FKB]" in Japan".
Filed with NSE · · 3 pages · English
Biocon Limited has announced a distribution agreement with Sandoz for the exclusive rights to promote and sell Adalimumab BS Subcutaneous Injection in Japan. This agreement follows the completion of marketing and promotion by Viatris, which will transition responsibilities to Sandoz starting in February. The partnership aims to enhance Sandoz's immunology and biosimilar portfolio, contributing to sustainable business growth. Biocon Biologics has successfully integrated Viatris’ biosimilars business in multiple countries, marking a significant milestone in its operations.
Written by 6ix AI from the company’s filing. How 6ix writes summaries

Biocon Limited has informed the Exchange regarding a press release dated December 22, 2023, titled "Biocon Biologics Partners with Sandoz for the Distribution of Adalimumab BS Subcutaneous Injection [FKB]" in Japan".
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon